Search This Blog

Monday, June 5, 2017

Clinical Trial Data for Combination of Epacadostat and Opdivo® (nivolumab) Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer | BMS Newsroom

These data supported advancing the clinical development program for epacadostat and Opdivo in these types of cancer
Combination of IDO1 enzyme inhibition plus Opdivo was generally well-tolerated in patients with select advanced solid tumors


Clinical Trial Data for Combination of Epacadostat and Opdivo® (nivolumab) Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer | BMS Newsroom

No comments:

Post a Comment